^
Association details:
| Biomarker: | MET-ATXN7L1 fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Identification of a novel crizotinib-sensitive MET–ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing
Excerpt:
The tumor tissue was further subjected to NGS (3D Medicines, Shanghai, China), which showed MET–ATXN7L1 fusion (Figure 1)...Therefore, the patient underwent crizotinib treatment (250 mg/b.i.d. orally) in March 2017. After 1 month, chest CT scan images demonstrated a partial response to crizotinib according to RECIST 1.1...This is the first report of an MET–ATXN7L1 fusion case with lung adenocarcinoma who responded to crizotinib treatment.
DOI:
10.1093/annonc/mdy455
